U.S. Markets closed

Regulus Therapeutics Inc. (RGLS)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.10+0.12 (+12.24%)
At close: 4:00PM EDT

1.11 0.01 (0.91%)
After hours: 5:50PM EDT

People also watch
PTCTCEMPOMEDOVASVSTM

Regulus Therapeutics Inc.

10614 Science Center Drive
San Diego, CA 92121
United States
858-202-6300
http://www.regulusrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees92

Key Executives

NameTitlePayExercisedAge
Mr. Joseph P. HaganPres, CEO & Director623.86kN/A48
Dr. Timothy Michael Wright M.D., Ph.D.Chief R&D Officer252.75kN/A61
Mr. Daniel R. Chevallard CPAChief Financial OfficerN/AN/AN/A
Ms. Allison WeyVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Christopher Aker J.D.VP of Legal Affairs & Corp. Sec.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Corporate Governance

Regulus Therapeutics Inc.’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.